NeuPath Health Inc. (TSXV:NPTH)
Canada · Delayed Price · Currency is CAD | Market Cap | 33.71M +125.0% |
| Revenue (ttm) | 89.37M +19.7% |
| Net Income | 9.00K |
| EPS | 0.00 |
| Shares Out | 56.18M |
| PE Ratio | 3,745.39 |
| Forward PE | 7.74 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 17,000 |
| Open | 0.5900 |
| Previous Close | 0.6000 |
| Day's Range | 0.5900 - 0.6000 |
| 52-Week Range | 0.2300 - 0.6800 |
| Beta | 1.07 |
| Analysts | Buy |
| Price Target | 0.77 (+28.33%) |
| Earnings Date | Aug 14, 2026 |
About NeuPath Health
NeuPath Health Inc. provides chronic pain management services in Canada. It operates a network of medical clinics in Ontario and Alberta that offer assessments and rehabilitation services to patients with chronic pain, musculoskeletal/back injuries, sports-related injuries, and concussions. The company also provides workplace health services and independent medical assessments to employers and disability insurers, as well as legal practices through a network of health care providers comprising cardiologists, dentists, dermatologists, psychiatri... [Read more]
Financial Performance
In 2025, NeuPath Health's revenue was 87.19 million, an increase of 19.76% compared to the previous year's 72.81 million. Losses were -717,000, -1.51% less than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for NPTH stock is "Buy." The 12-month stock price target is $0.77, which is an increase of 28.33% from the latest price.
News
NeuPath Health Earnings Call Transcript: Q1 2026
Q1 2026 saw 11% revenue growth and 15% Adjusted EBITDA growth, with strong patient volume and capacity utilization gains. Expansion continues with a new Guelph facility and ongoing M&A activity, while gross margin faced pressure from higher staffing costs.
NeuPath Health Earnings release: Q1 2026
NeuPath Health released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
NeuPath Health Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference
A leading chronic pain network in Canada reported 20% revenue growth, improved margins, and strong cash flow, driven by expanding physician hours, technology investments, and targeted M&A. The business benefits from a highly fragmented market, low physician churn, and over 90% government-funded revenue.
NeuPath Health Earnings Call Transcript: Q4 2025
Revenue grew 20% to CAD 87.2M in 2025, with adjusted EBITDA up 56% and margin improvement. Growth is driven by physician recruitment, technology, and service expansion, with 2026 guidance for 8%-12% revenue growth and higher EBITDA margin.
NeuPath Health Earnings release: Q4 2025
NeuPath Health released its Q4 2025 earnings on March 26, 2026, summarizing the period's financial results.
NeuPath Health Slides: Investor presentation
NeuPath Health has posted slides in relation to its latest quarterly earnings report, which was published on March 26, 2026.
NeuPath Health Earnings Call Transcript: Q3 2025
Q3 saw 26% revenue growth and a 98% increase in adjusted EBITDA, driven by higher patient volumes and operational improvements. The company reduced net debt, expanded in Alberta, and is actively pursuing acquisitions, with a strong cash position and ongoing share buybacks.
NeuPath Health Earnings release: Q3 2025
NeuPath Health released its Q3 2025 earnings on November 13, 2025, summarizing the period's financial results.
NeuPath Health Earnings release: Q2 2025
NeuPath Health released its Q2 2025 earnings on August 14, 2025, summarizing the period's financial results.